The Perron Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carroll, William
NCT01017055: Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery

Recruiting
N/A
200
US
Voice and Swallowing evaluations
University of Alabama at Birmingham
Dysphagia, Dysphonia
12/24
06/25
Schultz, David M
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Completed
3
943
Europe, US
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution
GlaxoSmithKline
Infections, Meningococcal
11/23
11/23
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company, Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
AMBALS, NCT05959850: A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Recruiting
2
50
RoW
Ambroxol, Ambroxol Hydrochloride, Placebo
The Florey Institute of Neuroscience and Mental Health, Mobius Medical Pty Ltd., The University of Queensland
Amyotrophic Lateral Sclerosis
06/24
12/24
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Recruiting
2
350
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity
01/26
10/26
NCT05882695: Study of SPG302 in Healthy Volunteers and ALS Participants

Active, not recruiting
1
112
RoW
SPG302, Placebo
Spinogenix, Novotech (Australia) Pty Limited
Amyotrophic Lateral Sclerosis
05/25
12/25
REALITY, NCT03876054: Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

Recruiting
N/A
2000
Europe, US, RoW
Spinal cord stimulation (SCS), Dorsal root ganglion stimulation (DRG)
Abbott Medical Devices
Chronic Pain
06/29
12/29
Walters, Susan
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Needham, Merrilee
ACTRN12620001226998p: Sirolimus in Inclusion Body Myositis (IBM)

Not yet recruiting
3
140
 
The Perron Institute for Neurological and Translational Science , National Health and Medical Research Council
Inclusion Body Myositis
 
 
ACTRN12620001226998: Sirolimus in Inclusion Body Myositis (IBM)

Recruiting
3
140
 
The Perron Institute for Neurological and Translational Science , National Health and Medical Research Council
Inclusion Body Myositis
 
 
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
IBM-FRS, NCT04789070: Phase III Trial of Sirolimus in IBM

Recruiting
3
140
US, RoW
Sirolimus, Rapamune, Placebo
University of Kansas Medical Center, The Perron Institute
Inclusion Body Myositis
09/26
09/26
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
Lighthouse III, NCT06658977: RolloverTreatment with Triumeq for People with ALS Following the Lighthouse II Trial

Not yet recruiting
3
70
RoW
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Macquarie University, Australia
Amyotrophic Lateral Sclerosis, ALS
12/26
12/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
ACTRN12622000093785p: Does Inspiratory Muscle Training Improve Lung Function and Quality of Life in people with Inclusion Body Myositis?

Not yet recruiting
N/A
15
 
IIID Murdoch, IIID Murdoch
Inclusion body myositis
 
 
ACTRN12619001691134p: Testosterone to treat men with painful osteoarthritis of the knee

Not yet recruiting
N/A
30
 
Lawley Pharmaceuticals Pty Ltd, Research Development Unit, Department of Health
Knee Osteoarthritis
 
 
ACTRN12619001691134: Testosterone to treat men with painful osteoarthritis of the knee

Not yet recruiting
N/A
30
 
Lawley Pharmaceuticals Pty Ltd, Research Development Unit, Department of Health
Knee Osteoarthritis
 
 
ACTRN12622000093785: Does Inspiratory Muscle Training Improve Lung Function and Quality of Life in people with Inclusion Body Myositis?

Completed
N/A
15
 
IIID Murdoch, IIID Murdoch
Inclusion body myositis
 
 

Download Options